Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-Pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-Pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

Three Outcome Health Execs Sentenced in $1B Pharma Advertising Fraud Case

  • Post author:PacConAdmin
  • Post published:July 2, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

Three former executives of Chicago-based tech startup Outcome Health have been sentenced for their roles in a six-year scheme involving approximately $1 billion in fraudulently obtained funds gained from a…

Continue ReadingThree Outcome Health Execs Sentenced in $1B Pharma Advertising Fraud Case

Cassava Consultant Indicted for Fraud, SEC Filing Reveals Drug Data Discrepancies

  • Post author:PacConAdmin
  • Post published:July 2, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

Hoau-Yan Wang, a former paid consultant at Cassava Science and professor at the City University of New York (CUNY), is now the subject of a federal indictment charging that he…

Continue ReadingCassava Consultant Indicted for Fraud, SEC Filing Reveals Drug Data Discrepancies

Supremes Water Down Regulatory Agency Authority

  • Post author:PacConAdmin
  • Post published:July 1, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

The Supreme Court’s reversal of a 40-year-old precedent that had smoothed the regulatory agency pathway now makes it easier for courts to step in with their own interpretation of a…

Continue ReadingSupremes Water Down Regulatory Agency Authority

FDA Delivers Long-Anticipated Guidance on Diversity Action Plans

  • Post author:PacConAdmin
  • Post published:July 1, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

The FDA has published overdue draft guidance on developing diversity action plans for clinical trials, moving the agency a step closer to the statutory mandate that all phase 3 trials…

Continue ReadingFDA Delivers Long-Anticipated Guidance on Diversity Action Plans

CHMP Withholds Support for Drugs Aimed at Duchenne Muscular Dystrophy, ALS

  • Post author:PacConAdmin
  • Post published:July 1, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

The EU’s Committee for Medicinal Products for Human Use (CHMP) isn’t supporting two drugs intended to treat patients with amyotrophic lateral sclerosis (ALS) and Duchenne muscular — diseases that have…

Continue ReadingCHMP Withholds Support for Drugs Aimed at Duchenne Muscular Dystrophy, ALS

Legislative Update — Week of July 1, 2024

  • Post author:PacConAdmin
  • Post published:July 1, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

As the second session of the 118th Congress begins, FDAnews will track important pending legislation, that has been acted on since Dec. 31, 2023 to keep you updated on laws…

Continue ReadingLegislative Update — Week of July 1, 2024

Three Class I Recalls With Device Corrections, Not Removals, Including a Philips Ventilator

  • Post author:PacConAdmin
  • Post published:July 1, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

Another Philips ventilator recall was deemed Class I by the FDA for an issue that has led to 15 reported injuries and one death. Source: Drug Industry Daily

Continue ReadingThree Class I Recalls With Device Corrections, Not Removals, Including a Philips Ventilator

FDA Approves Innovations in COPD Drugs, In-Office Hep C Test

  • Post author:PacConAdmin
  • Post published:June 28, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

The FDA has approved Verona Pharma’s Ohtuvayre (ensifentrine), the first inhaled maintenance chronic obstructive pulmonary disease (COPD) drug in more than two decades, and granted marketing authorization of a novel…

Continue ReadingFDA Approves Innovations in COPD Drugs, In-Office Hep C Test

Design of Drug-Device Combo Performance Measures is Subject of FDA Draft Guidance

  • Post author:PacConAdmin
  • Post published:June 28, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

Assuring the consistent performance of a drug-delivery combination product through the outputs that measure that performance is the focus of an FDA draft guidance released July 1. Source: Drug Industry…

Continue ReadingDesign of Drug-Device Combo Performance Measures is Subject of FDA Draft Guidance

Regulatory Update — Week of June 24, 2024

  • Post author:PacConAdmin
  • Post published:June 28, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

This week, the FDA published a final guidance for small businesses on LDTs. The long-awaited draft guidance on diversity in clinical trials was also published. The agency modified its list…

Continue ReadingRegulatory Update — Week of June 24, 2024
  • Go to the previous page
  • 1
  • …
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • …
  • 143
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.